iFAST Diagnostics bags £5M to speed up infection testing and tackle antimicrobial resistance
UK biotech iFAST Diagnostics has closed a £5 million funding round. iFAST is addressing the $4 billion (and growing) Antimicrobial Susceptibility Testing (AST) market. It has developed a test deliveri...
Amidst growing global awareness and concern over antimicrobial resistance, there is an urgent demand for rapid and effective diagnostic tools to combat this crisis.
This funding enables the advancement of critical diagnostic technology that can significantly improve treatment outcomes for infections and slow the development of antimicrobial resistance, impacting global health and economic stability.
The development of faster, more accurate antimicrobial susceptibility testing will allow for more targeted and effective treatment strategies, potentially reducing the overuse of broad-spectrum antibiotics.
- · iFAST Diagnostics
- · Biotech sector
- · Patients with infections
- · Healthcare providers
- · Antibiotic-resistant bacteria
Faster diagnostics lead to more appropriate antibiotic prescriptions, reducing treatment failures and healthcare costs.
A decrease in antibiotic resistance could revitalize the efficacy of existing medications and extend the lifespan of new antibiotic classes.
Reduced antimicrobial resistance could lessen the burden on future healthcare systems, allowing resources to be reallocated to other public health challenges.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Tech.eu